ストックスクリーナーアプリを入手
16.64
3.94%
0.63
アフターアワーズ：
16.77
0.13
+0.78%
前日終値:
$16.01
開ける：
$16.12
24時間の取引高:
2.39M
Relative Volume:
1.11
時価総額：
$1.68B
収益：
$352.57M
当期純損益:
$-143.01M
株価収益率:
-9.1934
EPS:
-1.81
ネットキャッシュフロー:
$-153.40M
1週間 パフォーマンス:
-6.62%
1か月 パフォーマンス:
-22.75%
6か月 パフォーマンス:
-45.32%
1年 パフォーマンス:
-32.14%
1日の値動き範囲:
$16.04
$17.12
1週間の範囲:
$15.60
$18.17
52週間の値動き範囲:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
16.64 | 1.73B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-10 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating - MSN
Cantor Fitzgerald reiterates Overweight rating on Beam Therapeutics stock - Investing.com
Beam Therapeutics (BEAM) Gets a Buy from Bernstein - The Globe and Mail
Beam Therapeutics Stock Surges After FDA Grants RMAT Designation - MSN
Cathie Wood's ARK Invest ETFs Buy $46.2M in Biotech Stocks, Trim Defense Exposure - AInvest
Technical signs of recovery in Beam Therapeutics Inc.July 2025 Outlook & AI Powered Trade Plan Recommendations - Newser
Using data tools to time your Beam Therapeutics Inc. exitWeekly Trading Summary & Real-Time Volume Trigger Notifications - Newser
Measuring Beam Therapeutics Inc.’s beta against major indices2025 Price Action Summary & Smart Investment Allocation Tips - Newser
What does recent volatility data suggest for Beam Therapeutics Inc.July 2025 Short Interest & AI Enhanced Trade Execution Alerts - Newser
Is Beam Therapeutics Inc. stock bottoming outJuly 2025 Outlook & Daily Momentum Trading Reports - Newser
Beam Therapeutics: Navigating Risks and Innovation in Gene Editing - AInvest
Beam Therapeutics: A Slow-Developing Story (NASDAQ:BEAM) - Seeking Alpha
Beam Therapeutics Inc. stock prediction for this weekEarnings Performance Report & Free AI Powered Buy and Sell Recommendations - Newser
Evaluating Beam Therapeutics Inc. with trendline analysisTrade Entry Report & Fast Entry High Yield Stock Tips - Newser
Should you hold or exit Beam Therapeutics Inc. nowEarnings Performance Report & AI Powered Market Entry Strategies - Newser
Will Beam Therapeutics Inc. rebound enough to break evenMarket Performance Summary & Weekly Setup with High ROI Potential - Newser
Is Beam Therapeutics Inc. a strong candidate for buy and hold2025 Earnings Impact & Detailed Earnings Play Strategies - thegnnews.com
Understanding Beam Therapeutics Inc.’s price movement2025 Momentum Check & Free Community Consensus Stock Picks - Newser
Is Beam Therapeutics Inc. likely to announce a buybackMarket Trend Report & Short-Term High Return Strategies - sisa-n.com
Applying Wyckoff theory to Beam Therapeutics Inc. stockDollar Strength & Risk Managed Investment Strategies - Newser
Chart overlay techniques for tracking Beam Therapeutics Inc.Insider Selling & Daily Chart Pattern Signal Reports - Newser
Is Beam Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideJuly 2025 Action & Free Growth Oriented Trading Recommendations - Newser
FMR LLC Boosts Stake in Beam Therapeutics Amidst Financial Challenges - AInvest
BEAM-101 Receives RMAT for the Treatment of Sickle Cell Disease - Pharmacy Times
Beam Therapeutics announces U.S. FDA granted RMAT to BEAM-101 - TipRanks
Beam Therapeutics stock surges after FDA grants RMAT designation By Investing.com - Investing.com Canada
Beam Therapeutics stock surges after FDA grants RMAT designation - Investing.com India
Beam Therapeutics Gets FDA Regenerative Medicine Status for BEAM-101 to Treat Sickle Cell Disease - MarketScreener
Beam gains FDA Regenerative Medicine Advanced Therapy status for sickle cell treatment - Seeking Alpha
Beam Therapeutics' Sickle Cell Treatment Gets FDA's Generative Medicine Advanced Therapy Designation - MarketWatch
Beam Therapeutics up after FDA's tag for sickle cell therapy - TradingView
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | BEAM Stock News - GuruFocus
FDA grants RMAT designation to Beam Therapeutics’ sickle cell therapy By Investing.com - Investing.com Australia
FDA grants RMAT designation to Beam Therapeutics’ sickle cell therapy - Investing.com
Beam Therapeutics Announces U.S. FDA Regenerative Medicine - GlobeNewswire
Beam's Sickle Cell Gene Therapy Gets FDA Speed Boost After Strong Trial Data in 30 Patients - Stock Titan
Unlocking 100%+ Upside: Top Analysts Reveal Small-Cap Stocks to Double Your Money - AInvest
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Yahoo Finance
Will Beam Therapeutics Inc. benefit from government policyROI-Driven Capital Plans - thegnnews.com
Applying Elliott Wave Theory to Beam Therapeutics Inc.Momentum Entry Alerts with Risk Control - Newser
Beam Therapeutics (NASDAQ:BEAM) Price Target Cut to $21.00 by Analysts at Barclays - MarketBeat
Has Beam Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewDaily Market Momentum Summary and Strategy - Newser
Beam Therapeutics Inc. Recovery Gathers Momentum on Chart SignalsFree Access to Community - beatles.ru
Cantor Fitzgerald Issues Negative Outlook for BEAM Earnings - Defense World
Using flow based indicators on Beam Therapeutics Inc.Free Fast Exit and Entry Strategy Guide - Newser
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark - MSN
William Blair Lifts Earnings Estimates for Beam Therapeutics - Defense World
Beam Therapeutics: Analyst Maintains Buy Rating Amid Promising Trials and Solid Financials - AInvest
Beam Therapeutics: A Promising Genetic Medicine Player with Multiple Upcoming Catalysts - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Raises Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - 富途牛牛
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
Beam Therapeutics Inc (BEAM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Simon Amy | Chief Medical Officer |
Jul 03 '25 |
Sale |
20.12 |
876 |
17,625 |
64,864 |
| Simon Amy | Chief Medical Officer |
Jul 01 '25 |
Sale |
16.94 |
374 |
6,336 |
65,740 |
| Bellon Christine | Chief Legal Officer |
Apr 01 '25 |
Sale |
18.35 |
5,674 |
104,122 |
117,294 |
| Evans John M. | CEO |
Apr 01 '25 |
Sale |
18.35 |
30,663 |
562,684 |
986,249 |
| Ciaramella Giuseppe | President |
Apr 01 '25 |
Sale |
18.35 |
7,434 |
136,418 |
190,216 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '25 |
Sale |
18.35 |
3,015 |
55,330 |
44,512 |
| Simon Amy | Chief Medical Officer |
Apr 02 '25 |
Sale |
17.73 |
20,997 |
372,294 |
65,742 |
| Simon Amy | Chief Medical Officer |
Apr 01 '25 |
Sale |
18.35 |
9,566 |
175,542 |
86,739 |
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):